• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Immutep Share Price Soars on US FDA Fast Track Designation (ASX:IMM)

Like 0

By Lachlann Tierney, Thursday, 08 April 2021

The Immutep Ltd [ASX:IMM] share price is up 11.4% today after securing fast track designation from the US FDA for its eftilagimod alpha product. IMM shares were up as much as 17% in early trade...

The Immutep Ltd [ASX:IMM] share price is up 11.4% today after securing fast track designation from the US FDA for its eftilagimod alpha product.

The biotechnology company, which develops immunotherapy treatments for cancer, infectious disease and autoimmune disease, stated the fast track designation can expedite development and review with the US FDA.

IMM shares were up as much as 17% in early trade.

After falling in early March, IMM shares are currently up 55% over the last month and up 250% over the last 12 months.

ASX IMM Share Price Chart - Immutep Source: Tradingview.com

Immutep’s efti product achieves fast track designation

Immutep revealed that its lead product candidate — eftilagimod alpha (efti), a soluble LAG-3 protein — received the fast track designation in first line recurrent or metastatic HNSCC from the United States Food and Drug Administration (FDA).

We reveal four little-known small-cap stocks that cannot be ignored…Download your free report now.

Head and neck squamous cell carcinoma (HNSCC) develop in the mucous membranes of the mouth, nose and throat.

Squamous cells are found in the outer layer of the skin in the mucous membranes.

Immutep stated that the fast track was granted because of efti’s ‘potential to address an unmet medical need, as evidenced by encouraging data indicating a positive risk benefit ratio.’

Immutep noted that the data package evaluated by the FDA ‘included promising results’ from Part C of Immutep’s Phase II TACTI-002 trial assessing efti in combination with KEYTRUDA (pembrolizumab).

As the company explained in the release, an FDA fast track designation is awarded to help ‘important new therapies reach patients faster.’

Immutep secures European patent grant

Yesterday, Immutep announced that the European Patent Office granted the company a patent for one of its antibody products.

As the company explained, the claims of the patent are directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody, out-licensed to Novartis AG.

IMP701 is a therapeutic antibody that can ‘remove two brakes that prevent the immune system from responding to and killing cancer cells.’

The patent is co-owned by Novartis AG and Immutep and expires on 28 July 2036.

Immutep share price outlook

Immutep noted in today’s announcement that its new Phase IIb trial in first line HNSCC, TACTI-003 to evaluate efti in combination with KEYTRUDA is expected to start in mid-2021.

The trial will run in collaboration with MSD, a subsidiary of Merck & Co.

Additionally, the company’s humanised form of IMP701 is currently being evaluated by Novartis in several Phase 1 and Phase 2 clinical trials.

The bidding up of IMM shares this week suggests investors are bullish on Immutep’s progress.

In a sector so contingent on regulatory approvals, investors may have seen the FDA fast tracking one of Immutep’s products as a positive indication the company is progressing.

However, as with any junior biotechnology stock, many more hurdles are coming and Immutep will have to scale each one successfully to commercialise its products.

No doubt investors will be eagerly watching Immutep’s upcoming clinical results.

If you want further coverage and analysis of biotechnology stocks and related investment ideas, then I suggest checking out our free, daily e-letter.

It’s a publication that brings you investing news you’ll be hard-pressed to find anywhere else.

Regards,

Lachlann Tierney,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Lion Clock says buy now for the big pay off later
    By Callum Newman

    Now is the time to be investing and following into this sector. According to the Lion investment clock, now’s the time to scoop up what you can and surf the rising liquidity wave.

  • Cashflow Gems: Focus on Mining Juniors That Own the Golden Goose
    By James Cooper

    Exploration success hinges on continuous drilling, and self-funding juniors have the edge. Discover how these companies leverage cash flow to advance projects without pausing, while their cash-strapped competitors face hibernation.

  • Tick, tock: there’s a boom brewing in one sector…
    By Callum Newman

    All the old hands say you’re supposed to buy resources when they’re down in the dumps. That’s the theory. It’s the timing that’s the bitch. Here’s some help with that…

Primary Sidebar

Latest Articles

  • Lion Clock says buy now for the big pay off later
  • Cashflow Gems: Focus on Mining Juniors That Own the Golden Goose
  • Tick, tock: there’s a boom brewing in one sector…
  • Buy oil when there’s peace in the streets
  • Vicuña: The Greatest Mineral Discovery of Our Lifetime

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988